Pneumonia: Independent Evidence on Treatment and Vaccines
Adult pneumonia evidence on severity scoring, antibiotic duration, steroids and vaccines, graded by independence, with who funded each key trial.
Asthma & Respiratory
Independent, evidence-graded research on asthma and respiratory health — what primary studies and regulators show about triggers, management and supplements.
Bronchiectasis: Macrolides, Brensocatib & Who Funded the Trials
Long-term macrolides have the best independent evidence in bronchiectasis. Brensocatib is approved but rests on one maker-funded trial, and most supplements lack support.
Asthma Inhalers: Reliever Risk, Montelukast Warnings and Funding
Reliever-only asthma treatment carries a death risk, and as-needed combination inhalers cut flare-ups. Who funded the key trials, and the montelukast warnings.
Chronic Cough: Independent Evidence on Causes, Drugs & Funding
Most chronic cough has a treatable cause. For unexplained cough, gabapentin and speech therapy rest on small trials, and gefapixant helps modestly in maker-sponsored trials.
Allergic Rhinitis: Independent Evidence on Treatment and Funding
Nasal steroid sprays beat antihistamines for nasal symptoms in the best trials, and allergy tablets help moderately. Who funded each source is shown.
COPD: Independent Evidence on Inhalers, Oxygen & Funding
Long-term oxygen did not help moderate desaturation in a public trial, while triple inhaler benefits come mainly from sponsor-funded trials. Pneumonia is the main inhaler concern.
Chronic Rhinosinusitis: Adult Care and Adjunct Evidence
Adult CRS guidance, saline and nasal steroids, specific biologic comparisons and limited supplement trials, with funding, access and reporting limits.
Asthma Supplements: Nutritional Roles, Evidence Limits and Safety
Asthma supplements have limited, ingredient-specific evidence. Vitamin D has a nutritional role; IV magnesium is a selected hospital adjunct. Prescribed inhalers and the action plan remain essential.
Asthma Prevention and Management: Evidence and Safety Guide
Key takeaways WHO estimates asthma affected 363 million people in 2023 and caused 442,000 deaths, with most deaths occurring in low- and lower-middle-income countries, where under-diagnosis and under-treatment are major problems (WHO asthma fact sheet). GINA states SABA-only (reliever-only) treatment raises exacerbation risk, worsens lung function, and increases asthma-death risk — low-dose ICS or as-needed … Read more